CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature
- PMID: 20009603
- DOI: 10.1097/ID.0b013e3181c6837c
CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part I: biological concepts with a review of the literature
Abstract
Biochemical markers of bone metabolism have been used in medicine to evaluate and provide treatment to patients with metabolic bone diseases, such as osteoporosis. Serum cross-linked C-telopeptide of type I collagen is a marker of osteoclast activity and is used to assess the level of bone resorption. Recently, in oral and maxillofacial surgery, it was proposed that the levels of serum cross-linked C-telopeptide of type I collagen may predict the subsequent risk of developing osteonecrosis of the jaws after oral surgery procedures for patients taking oral bisphosphonates. The astute clinician must critically review the scientific literature and must decide if biochemical markers of bone resorption are of benefit in managing the oral surgery patient on bisphosphonates.
Similar articles
-
CTX biochemical marker of bone metabolism. Is it a reliable predictor of bisphosphonate-associated osteonecrosis of the jaws after surgery? Part II: a prospective clinical study.Implant Dent. 2010 Feb;19(1):29-38. doi: 10.1097/ID.0b013e3181cec8bc. Implant Dent. 2010. PMID: 20147814 Clinical Trial.
-
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.J Oral Maxillofac Surg. 2007 Dec;65(12):2397-410. doi: 10.1016/j.joms.2007.08.003. J Oral Maxillofac Surg. 2007. PMID: 18022461
-
Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates.J Oral Maxillofac Surg. 2010 Sep;68(9):2241-7. doi: 10.1016/j.joms.2010.05.043. J Oral Maxillofac Surg. 2010. PMID: 20728033
-
Bisphosphonates and bisphosphonate induced osteonecrosis.Oral Maxillofac Surg Clin North Am. 2007 Nov;19(4):487-98, v-vi. doi: 10.1016/j.coms.2007.07.003. Oral Maxillofac Surg Clin North Am. 2007. PMID: 18088900 Review.
-
A review of bisphosphonate-associated osteonecrosis of the jaws and its management.J Can Dent Assoc. 2007 Jun;73(5):417-22. J Can Dent Assoc. 2007. PMID: 17555652 Review.
Cited by
-
Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment.J Bone Metab. 2019 Nov;26(4):213-224. doi: 10.11005/jbm.2019.26.4.213. Epub 2019 Nov 30. J Bone Metab. 2019. PMID: 31832387 Free PMC article. Review.
-
The 2024 Guidelines for Osteoporosis - Korean Society of Menopause: Part I.J Menopausal Med. 2024 Apr;30(1):1-23. doi: 10.6118/jmm.24000. J Menopausal Med. 2024. PMID: 38714490 Free PMC article. Review. No abstract available.
-
The facial skeleton in patients with osteoporosis: a field for disease signs and treatment complications.J Osteoporos. 2011 Feb 16;2011:147689. doi: 10.4061/2011/147689. J Osteoporos. 2011. PMID: 21403823 Free PMC article.
-
Defining the epidemiology of bisphosphonate-associated osteonecrosis of the jaw: prior work and current challenges.Osteoporos Int. 2013 Jan;24(1):237-44. doi: 10.1007/s00198-012-2042-6. Epub 2012 Jun 16. Osteoporos Int. 2013. PMID: 22707065 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical